for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc

GSK.L

Latest Trade

1,729.40GBp

Change

22.60(+1.32%)

Volume

5,230,580

Today's Range

1,704.80

 - 

1,731.20

52 Week Range

1,408.80

 - 

1,796.40

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
1,706.80
Open
1,718.80
Volume
5,230,580
3M AVG Volume
150.48
Today's High
1,731.20
Today's Low
1,704.80
52 Week High
1,796.40
52 Week Low
1,408.80
Shares Out (MIL)
4,989.32
Market Cap (MIL)
85,157.74
Forward P/E
14.05
Dividend (Yield %)
--

Next Event

Q4 2019 GlaxoSmithKline PLC Earnings Release

Latest Developments

More

GSK seeks FDA approval for investigational HIV treatment

Hikma Pharmaceutical Says Completed FDA Response For Generic Advair

Exagen Inc Extends Collaboration Agreement With Glaxosmithkline For A Third Year

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Industry

Biotechnology & Drugs

Contact Info

G S K House, 980 Great West Road

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.52 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2016

27.9K

2017

30.2K

2018

30.8K

2019(E)

33.5K
EPS (GBp)

2016

102.400

2017

111.800

2018

119.400

2019(E)

121.473
Price To Earnings (TTM)
18.18
Price To Sales (TTM)
2.58
Price To Book (MRQ)
7.23
Price To Cash Flow (TTM)
10.22
Total Debt To Equity (MRQ)
280.74
LT Debt To Equity (MRQ)
210.95
Return on Investment (TTM)
11.20
Return on Equity (TTM)
7.30

Latest News

Latest News

GSK seeks FDA approval for investigational HIV treatment

GlaxoSmithKline Plc said on Thursday its HIV unit has submitted a new drug application to the U.S. Food and Drug Administration seeking approval for fostemsavir, an experimental treatment for HIV in adults.

GSK sees breakthrough in shingles vaccine output in 2024

GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.

GSK eyes 'step change' in shingles vaccine output in 2024

GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a "step change" in production.

Merck KGaA raises 2019 guidance after Versum takeover

German science and technology company Merck KGaA <MRCG.DE> raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials <VSM.N> in October.

GSK raises profit forecast after shingles vaccine sales boost

GlaxoSmithKline <GSK.L> on Wednesday raised its annual profit forecast for the second time this year as sales of its shingles vaccine beat expectations and older medicines, including HIV treatments, continued to sell well.

GSK lifts annual profit forecast after Q3 beat

GlaxoSmithKline Plc on Wednesday raised its annual profit forecast for the second time this year as soaring sales of its Shingles vaccine helped offset a hit from generic competition to its blockbuster asthma drug Advair.

GlaxoSmithKline starts late-stage trial for experimental antibiotic

GlaxoSmithKline Plc <GSK.L> said on Monday it has begun a late-stage study testing its experimental antibiotic in patients with urinary tract infections and gonorrhoea, a type of sexually transmitted infection.

GSK gets FDA nod for wider use of ovarian cancer drug Zejula

GlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.

U.S. FDA okays wider use of GSK ovarian cancer drug

GlaxoSmithKline said on Wednesday U.S. regulators approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.

Timeline: Popular heartburn medicine Zantac pulled off store shelves

The U.S. Food and Drug Administration and international health authorities are investigating the safety of Zantac heartburn medicine, also sold generically as ranitidine, after finding a probable cancer-causing impurity in the drug.

GSK to sell two vaccines in $1.1 billion deal to focus on newer treatments

GlaxoSmithKline will sell two travel vaccines to Bavarian Nordic for up to 955 million euros ($1.1 billion), the British firm said on Monday, as it looks to bolster its push into the lucrative cancer drug market.

GSK to sell two travel vaccines to Danish biotech firm

GlaxoSmithKline Plc said on Monday it will sell two travel vaccines to Denmark-based biotechnology company Bavarian Nordic for an upfront payment of 301 million euros ($335.71 million).

GSK recalls popular heartburn drug Zantac globally after cancer scare

GlaxoSmithKline <GSK.L> on Tuesday said it is recalling the popular heartburn medicine Zantac in all markets as a "precaution", days after the U.S. Food and Drug Administration found "unacceptable" levels of probable cancer-causing impurity in the drug.

GSK recalls popular heartburn medicine Zantac - U.K. medicines watchdog

GlaxoSmithKline Plc is recalling its heartburn medicine Zantac as a "precautionary measure" due to a probable cancer-causing impurity in the drug, Britain's medicines watchdog said on Tuesday.

Vectura, Sandoz win ruling on inhaler packaging case against GSK

Vectura Group said on Friday a British court had ruled in its favor on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.

Vectura, Sandoz gets favourable ruling in inhaler packaging case against GSK

Vectura Group said on Friday a British court had ruled in its and partner Sandoz's favour over the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.

UK shares little changed, GSK gains

UK shares were steady on Monday as investors largely opted for a wait-and-watch approach amid simmering U.S.-China trade tensions and Brexit worries, and a lack of significant corporate news.

GlaxoSmithKline's cancer therapy cuts risk of disease progression or death by 38%

GlaxoSmithKline plc said on Monday its maintenance therapy for a form of ovarian cancer reduced the risk of disease progression or death by 38% in a late-stage study in cancer patients.

Results of GSK and AstraZeneca trials may widen ovarian cancer drug use

GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.

Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use

GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up